Research articleThe role of Thallium-201 scintigraphy and Tc-99m pentavalent dimercaptosuccinic acid in diagnosis and grading of chondrosarcoma
Introduction
Chondrosarcoma is a cartilage forming malignant neoplasm of the bone [1]. It constitutes about a quarter of all primary bone tumours, with a peak incidence between the third and seventh decades of life [2]. Radiological evaluation of the grade of malignancy in cartilaginous tumours may be limited [1,3]. The differences in cortical scalloping, expansion or thinning between enchondroma and low-grade chondrosarcoma on morphologic tumour images can be subtle [1,4]. Furthermore, biopsy samples are prone to sampling error and under-grading due to the limitations of anatomical imaging in detecting the most malignant area of the tumour [5].
It is important to understand that the treatment of cartilaginous tumours depends on the diagnosis [6]. The vast majority of enchondromas are either left untreated or managed with intralesional curettage with a low recurrence rate [7]. If the clinical, radiological and histological assessments are indicative of a chondrosarcoma, the lesion should be treated with a wide resection [8]. Incorrect diagnosis and/or grading may result in under- or over-treatment of cartilaginous tumours, which may later manifest as local recurrence or unnecessary loss of function respectively [9]. Consequently, a more accurate means of preoperative assessment is sought after for guiding clinical decision-making and optimising patient outcome [3].
Functional imaging is a medical imaging technique of measuring or detecting metabolic processes through the use of radiotracers [10]. Thallium-201 and bivalent DMSA (V) scans have been traditionally utilised for assessing cardiac [11] and renal functions [12] respectively. In cartilaginous tumours, they have shown to offer a direct assessment of tumour metabolic activity [13,14]. There are a few studies that have investigated the uptake of Thallium-201 and/or DMSA (V) in chondrosarcomas [3,[15], [16], [17]]. These studies have been conducted with relatively small sample sizes (range 22–92) and thus any statistically significant results may lack clinical applicability.
The objective of this study is to elucidate the value of Thallium-201 and Tc-99 m DMSA (V) individually and in combination for the diagnosis and grading of chondrosarcomas.
Section snippets
Subjects and study protocol
232 patients who were diagnosed with pathologically proven cartilaginous tumours of the bone between January 2000 and December 2018 at a single sarcoma centre (Melbourne, Australia) were retrospectively evaluated. Cartilaginous tumours of soft tissues such as synovial chondromatosis were outside the scope of this study. 35 patients with chondromyxoid fibroma and chondroblastoma were excluded prior to the extraction of imaging data. This is due to their dissimilar histologic matrix, containing
Results
Results are presented separately and in combination for Thallium-201 scan and Tc-99 m DMSA (V).
Discussion
The distinction between grade 1 chondrosarcoma and enchondroma on anatomical imaging can be difficult despite the various anatomical imaging features described such as ill-defined margins, popcorn calcifications, lobulated contour and scalloping [22,23]. In a recent study involving 53 cartilaginous tumours, the sensitivities of plain radiography and MRI were reported to be 21 % and 58 % respectively for correctly diagnosing grade 1 chondrosarcomas [4]. Similarly, a poor discriminating power of
Conclusion
The uptake characteristics of Thallium-201 and DMSA (V) scintigraphy were explored. We found four important results in our study. Firstly, Thallium-201 uptake had 7.92 times greater odds of grade 1 chondrosarcomas than enchondromas. Secondly, positive Thallium-201 scan was significantly associated with the odds of higher grade (2–3) compared to grade 1 chondrosarcomas. Thirdly, DMSA (V) uptake individually was not associated with grade 1 chondrosarcoma nor higher grade chondrosarcomas. Lastly,
Declaration of Competing Interest
I Jo declares that she has no conflict of interest. S Schlitch declares that he has no conflict of interest. G Powell declares that he has no conflict of interest. C Di Bella declares that she has no conflict of interest. G Pang declares that he has no conflict of interest. T Spelman declare that he has no conflict of interest. PF Choong has received institutional research grants from Johnson & Johnson P/L and Medacta AB, and is a member of the Surgeon Advisory Board for Oncology for Stryker
Acknowledgements
This study has not received any funding. However, we declare that one of the authors has received institutional research grants from Johnson & Johnson P/L and MEdacta AB, and is a member of the Surgeon Advisory Board for Oncology for Stryker Corporation.
References (40)
Can imaging criteria distinguish enchondroma from grade 1 chondrosarcoma?
Eur. J. Radiol.
(2015)- et al.
Chondroblastoma: varied histologic appearance, potential diagnostic pitfalls, and clinicopathologic features associated with local recurrence
Ann. Diagn. Pathol.
(2003) Applications of PET/CT and PET/MR imaging in primary bone malignancies
PET Clin.
(2018)The design of a pentavalent 99mTc− dimercaptosuccinate complex as a tumor imaging agent
Int. J. Nucl. Med. Biol.
(1985)- et al.
Chondrosarcoma of bone
Cancer Treat. Res.
(2014) From the archives of the AFIP: imaging of primary chondrosarcoma: radiologic-pathologic correlation
Radiographics
(2003)Tumor grade-related thallium-201 uptake in chondrosarcomas
Ann. Nucl. Med.
(2010)Is needle biopsy clinically useful in preoperative grading of central chondrosarcoma of the pelvis and long bones?
Clin. Orthop. Relat. Res.
(2017)- et al.
FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients
Eur. J. Nucl. Med. Mol. Imaging
(2004) Surgical treatment of grade I central chondrosarcoma
Clin. Orthop. Relat. Res.
(2010)
Low risk of recurrence of enchondroma and low-grade chondrosarcoma in extremities. 80 patients followed for 2-25 years
Acta Orthop. Scand.
The management of chondrosarcoma of bone
Clin. Orthop. Relat. Res.
Advantages in functional imaging of the brain
Front. Hum. Neurosci.
Dipyridamole–Thallium-201 scintigraphy in the prediction of future cardiac events after acute myocardial infarction
N. Engl. J. Med.
The normal 99mTc-DMSA renal image
Radiology
Diagnostic value of Thallium-201 scintigraphy in differentiating malignant bone tumors from benign bone lesions
Ann. Nucl. Med.
Both a visual and a semiquantitative analysis for differentiating benign from malignant chondrogenic bone tumors using Tc-99m (V) DMSA scintigraphy: a prospective study
Nucl. Med. Commun.
Characterization of cartilaginous tumors with 201Tl scintigraphy
Ann. Nucl. Med.
The role of thallium-201 and pentavalent dimercaptosuccinic acid for staging cartilaginous tumours
Int. Semin. Surg. Oncol.
Diagnostic value of Tc-99m (V) DMSA for chondrogenic tumors with positive Tc-99m HMDP uptake on bone scintigraphy
Clin. Nucl. Med.
Cited by (6)
Musculoskeletal Imaging
2023, Radiology-Nuclear Medicine Diagnostic Imaging: A Correlative ApproachThallium-induced DNA damage, genetic, and epigenetic alterations
2023, Frontiers in GeneticsAtypical cartilaginous tumors: Diagnosis and therapy
2022, OnkologieAtypical cartilaginous tumors: Diagnosis and therapy
2022, OnkologeCase Report: Reconstruction After Anterior Pubic Hemipelvectomy
2021, Frontiers in Surgery